CompletedNCT04944017
Ketamine studied for depression in Parkinson’s disease
About this title
Read the official source — NCT04944017This study assessed depression symptoms.
Medication studyAges 40–80United States
Understand this study
What did researchers investigate?
This study assessed depression symptoms.
Who was this study for?
This study was for people with depression. Listed age limits: 40 years to 80 years. Other eligibility criteria applied.
- Listed locations
- New HavenSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: November 23, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 51
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 40 Years to 80 Years
- Official registry ID
- NCT04944017
- Official title
Show the full official title
Ketamine for the Treatment of Depression in Parkinson's Disease (KET-PD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New Haven
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study assessed depression symptoms.
Who is behind this study?
The study sponsor is Yale University, a university.
Did this study involve medication?
Yes. The study involved medication, including Ketamine Infusion.
Who was this study for?
This study was for people with depression. Listed age limits: 40 years to 80 years. Other eligibility criteria applied.
